Stay updated on Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page
- Check5 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.8%
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check27 days agoChange DetectedThe web page has been updated to announce a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the previous version reference has been removed.SummaryDifference1%
- Check56 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check70 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding the efficacy and safety of pembrolizumab versus paclitaxel for advanced gastric cancer, and the addition of a new identifier for the protocol. The revision number has also been updated.SummaryDifference28%
- Check77 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page.